Sapporo Clinical Laboratory (TSE:9776) EBIT: 円752 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:9776 Sapporo Clinical Laboratory Inc TSE:9776
43 GF Score
Price 円1,960.00
GF Value 円1,041.47
! 4 Warning Signs
View Full Analysis

What is Sapporo Clinical Laboratory EBIT?

Sapporo Clinical Laboratory TSE:9776 43 EBIT is 円752 Mil as of Sep. 2025. GuruFocus rates TSE:9776 with a GF Score™ of 43/100 and a GF Value™ of 円1,041.47. The stock has 4 warning signs investors should review.

Sapporo Clinical Laboratory's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was 円393 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was 円752 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sapporo Clinical Laboratory's annualized ROC % for the quarter that ended in Sep. 2025 was 4.55%. Sapporo Clinical Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 8.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sapporo Clinical Laboratory's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 15.73%.


Sapporo Clinical Laboratory  (TSE:9776) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sapporo Clinical Laboratory's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=759.528 * ( 1 - 34.32% )/( (10971.826 + 10946.399)/ 2 )
=498.8579904/10959.1125
=4.55 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16450.937 - 2537.872 - ( 2941.239 - max(0, 3121.127 - 6636.148+2941.239))
=10971.826

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16786.417 - 2550.978 - ( 3289.04 - max(0, 3304.826 - 7047.834+3289.04))
=10946.399

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sapporo Clinical Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=785/( ( (8905.575 + max(829.363, 0)) + (8782.099 + max(744.648, 0)) )/ 2 )
=785/( ( 9734.938 + 9526.747 )/ 2 )
=785/9630.8425
=8.15 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2894.857 + 615.42 + 184.632) - (2537.872 + 0 + 327.674)
=829.363

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3026.891 + 585.824 + 146.079) - (2550.978 + 0 + 463.168)
=744.648

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sapporo Clinical Laboratory's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=751.914/4779.543
=15.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sapporo Clinical Laboratory EBIT Related Terms


Sapporo Clinical Laboratory EBIT Historical Data

* Premium members only.

The historical data trend for Sapporo Clinical Laboratory's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sapporo Clinical Laboratory EBIT Chart

Sapporo Clinical Laboratory Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,178.50 1,511.17 967.87 605.44 706.46

Sapporo Clinical Laboratory Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 390.12 215.32 347.05 359.41 392.50

Sapporo Clinical Laboratory EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sapporo Clinical Laboratory EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sapporo Clinical Laboratory's EV-to-EBIT falls into.


TSE:9776
43GF Score
Sapporo Clinical Laboratory Inc TSE:9776
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sapporo Clinical Laboratory EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円752 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円752 Mil mean?
Sapporo Clinical Laboratory (TSE:9776) has a EBIT of 円752 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sapporo Clinical Laboratory.
Is Sapporo Clinical Laboratory's EBIT too high?
Sapporo Clinical Laboratory's current EBIT is 円752 Mil. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's EBIT compare to competitors?
Sapporo Clinical Laboratory's EBIT of 円752 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sapporo Clinical Laboratory. Sapporo Clinical Laboratory's current EBIT is 円752 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current EBIT of 円752 Mil. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current EBIT is 円752 Mil. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current EBIT is 円752 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?

Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued. The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.

Key valuation signals for TSE:9776:

  • EBIT: 円752 Mil
  • GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sapporo Clinical Laboratory Business Description

Address 18-9-1 Nishi Kita-Gojo, Chuo-ku Sapporo, Hokkaido, Sapporo, JPN, 060 0005
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score

Get the complete analysis for TSE:9776

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,960.00
Price
円1,041.47
GF Value